{"hands_on_practices": [{"introduction": "Effective clinical decision-making relies on accurately interpreting diagnostic tests. This practice applies Bayes' theorem, a fundamental tool for updating belief in the presence of new evidence. By working through this problem, you will learn to formally combine your initial clinical suspicion (pre-test probability) with the known performance of a diagnostic test (sensitivity and specificity) to calculate a more precise post-test probability, which is essential for guiding subsequent management, such as the decision to proceed with surgery [@problem_id:5194835].", "problem": "A patient with generalized myasthenia gravis is being evaluated in a systemic surgery clinic to determine whether to proceed directly to an oncologic thymectomy or obtain additional staging before surgery. The decision hinges on the posterior (post-test) probability of thymoma after a positive chest Computed Tomography (CT) scan. In this practice environment, the pretest probability of thymoma, incorporating clinical phenotype and serologic markers, is assessed as $0.15$. A contemporary meta-analysis reports CT sensitivity $0.92$ and specificity $0.85$ for detecting thymoma that would merit oncologic resection. The CT is read as positive for a thymic mass consistent with thymoma.\n\nStarting solely from the core definitions of sensitivity and specificity as conditional probabilities, and Bayes’ theorem relating prior, likelihood, and posterior probabilities, derive the expression for the post-test probability of thymoma given a positive CT, and then compute its value for the above parameters. Express your final answer as a decimal and round to four significant figures.", "solution": "The problem is subjected to validation.\n\n**Step 1: Extract Givens**\n- Pre-test probability of thymoma: $0.15$\n- CT sensitivity for detecting thymoma: $0.92$\n- CT specificity for detecting thymoma: $0.85$\n- CT scan result: positive\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded**: The problem is based on Bayes' theorem, a fundamental principle of probability theory, and its application to medical diagnostics, using standard epidemiological definitions of sensitivity and specificity. The context is clinically relevant and the provided probabilities are within a realistic range. The problem is scientifically sound.\n- **Well-Posed**: The problem provides all necessary information (prior probability, sensitivity, and specificity) to calculate the posterior probability. The question is unambiguous and asks for a single, uniquely determinable value.\n- **Objective**: The problem is stated in objective, quantitative terms, free from subjective language or opinion.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A solution will be provided.\n\n**Solution Derivation**\n\nLet $T$ be the event that the patient has a thymoma.\nLet $T^c$ be the event that the patient does not have a thymoma.\nLet $C^+$ be the event that the Computed Tomography (CT) scan is positive.\nLet $C^-$ be the event that the CT scan is negative.\n\nThe information provided can be expressed in the language of conditional probability:\n1.  The pre-test probability of thymoma is the prior probability, $P(T)$.\n    $$P(T) = 0.15$$\n    From this, the prior probability of not having a thymoma is:\n    $$P(T^c) = 1 - P(T) = 1 - 0.15 = 0.85$$\n2.  Sensitivity is the probability of a positive test result given that the disease is present. This is the conditional probability $P(C^+|T)$.\n    $$P(C^+|T) = 0.92$$\n3.  Specificity is the probability of a negative test result given that the disease is absent. This is the conditional probability $P(C^-|T^c)$.\n    $$P(C^-|T^c) = 0.85$$\n\nThe objective is to find the post-test probability of thymoma given a positive CT scan, which is the posterior probability $P(T|C^+)$.\n\nAccording to Bayes' theorem, the posterior probability is given by:\n$$P(T|C^+) = \\frac{P(C^+|T) P(T)}{P(C^+)}$$\n\nThe term in the denominator, $P(C^+)$, is the total probability of a positive test result. It can be calculated using the law of total probability, which marginalizes over the presence or absence of the thymoma:\n$$P(C^+) = P(C^+ \\cap T) + P(C^+ \\cap T^c)$$\nUsing the definition of conditional probability, $P(A \\cap B) = P(A|B)P(B)$, we can write:\n$$P(C^+) = P(C^+|T)P(T) + P(C^+|T^c)P(T^c)$$\n\nWe are given $P(C^+|T)$ and $P(T)$, but we must derive $P(C^+|T^c)$. This term represents the probability of a positive test in a patient without a thymoma (the false positive rate). It is related to the specificity. For any given condition (in this case, absence of thymoma, $T^c$), the test must be either positive or negative. Therefore, the sum of their probabilities is $1$:\n$$P(C^+|T^c) + P(C^-|T^c) = 1$$\nSolving for the false positive rate:\n$$P(C^+|T^c) = 1 - P(C^-|T^c) = 1 - 0.85 = 0.15$$\n\nNow we can substitute all known values into the expression for the total probability $P(C^+)$:\n$$P(C^+) = (0.92)(0.15) + (0.15)(0.85)$$\n$$P(C^+) = 0.138 + 0.1275 = 0.2655$$\n\nFinally, we substitute the values for $P(C^+|T)$, $P(T)$, and $P(C^+)$ back into Bayes' theorem to find the desired posterior probability, $P(T|C^+)$. The full derived expression is:\n$$P(T|C^+) = \\frac{P(C^+|T)P(T)}{P(C^+|T)P(T) + P(C^+|T^c)P(T^c)}$$\n$$P(T|C^+) = \\frac{P(C^+|T)P(T)}{P(C^+|T)P(T) + (1 - P(C^-|T^c))(1-P(T))}$$\n\nComputing the numerical value:\n$$P(T|C^+) = \\frac{(0.92)(0.15)}{0.2655} = \\frac{0.138}{0.2655}$$\n$$P(T|C^+) \\approx 0.51977399...$$\n\nRounding the result to four significant figures, we get $0.5198$.", "answer": "$$\\boxed{0.5198}$$", "id": "5194835"}, {"introduction": "Acute respiratory distress in a patient with myasthenia gravis represents a critical emergency that demands rapid and accurate diagnosis. The cause can be either undertreatment (myasthenic crisis) or overtreatment (cholinergic crisis), and their management strategies are diametrically opposed. This clinical vignette challenges you to differentiate between these two life-threatening states based on a careful assessment of clinical signs and pathophysiological principles, reinforcing the skills needed for decisive and correct intervention in a high-stakes scenario [@problem_id:5194822].", "problem": "A $52$-year-old man with biopsy-proven anterior mediastinal thymic epithelial tumor consistent with thymoma and known Myasthenia Gravis (MG) with acetylcholine receptor (AChR) antibodies is scheduled for extended thymectomy. He has been on pyridostigmine $60 \\ \\mathrm{mg}$ every $4$ hours, recently increased to $90 \\ \\mathrm{mg}$ every $4$ hours due to perceived worsening fatigue. On the morning of admission, he develops acute bulbar and respiratory weakness with prominent salivation, bronchorrhea, abdominal cramping, diarrhea, miosis, bradycardia of $48 \\ \\mathrm{beats/min}$, and diffuse muscle fasciculations. His Forced Vital Capacity (FVC) is measured at $12 \\ \\mathrm{mL/kg}$ and Negative Inspiratory Force (NIF) at $-15 \\ \\text{cmH}_2\\text{O}$. Twelve hours after withholding cholinesterase inhibitors and supportive management for airway secretions, he improves transiently; subsequently, over $24$ hours he develops progressive dyspnea, dysphagia, and proximal limb weakness after an aspiration event with new right-lower-lobe infiltrate, minimal secretions, tachycardia of $110 \\ \\mathrm{beats/min}$, and dilated pupils. Repeat FVC is $10 \\ \\mathrm{mL/kg}$ and NIF is $-12 \\ \\text{cmH}_2\\text{O}$. He is hemodynamically stable with central venous access available. The surgical team aims to optimize him for thymectomy within the next $72$ hours if feasible.\n\nYou must select the most appropriate combined management strategy across both episodes to minimize perioperative respiratory failure and optimize surgical outcomes, grounding your reasoning in neuromuscular junction physiology, pharmacology of cholinesterase inhibitors, and immunomodulatory kinetics. Use the following fundamental bases:\n\n- Definition of neuromuscular transmission: presynaptic acetylcholine release binds postsynaptic nicotinic acetylcholine receptors; endplate depolarization triggers muscle action potential.\n- Role of acetylcholinesterase: enzymatic hydrolysis of acetylcholine in the synaptic cleft, limiting signal duration.\n- Pathophysiology of Myasthenia Gravis: autoimmune reduction of functional AChR density causing impaired neuromuscular transmission.\n- Pharmacodynamic effect of excess acetylcholine: depolarization block at nicotinic receptors and muscarinic overactivation with bradycardia, miosis, secretions.\n- Indications for ventilatory support: FVC less than $15 \\ \\mathrm{mL/kg}$ or NIF less than $-20 \\ \\text{cmH}_2\\text{O}$ signify impending respiratory failure warranting airway protection.\n- Mechanism and onset of therapeutic plasma exchange: removal of circulating immunoglobulins and complement with expected clinical improvement in approximately $24$ to $48$ hours.\n- Mechanism and onset of Intravenous Immunoglobulin (IVIG): immune modulation including Fc receptor blockade and complement modulation with typical onset over approximately $2$ to $5$ days.\n\nWhich option best aligns with these principles and the clinical timeline?\n\nA. During the initial episode, intubate for ventilatory support, administer intravenous atropine, and temporarily discontinue pyridostigmine; during the subsequent episode, initiate therapeutic plasma exchange to achieve rapid preoperative stabilization and proceed to thymectomy after clinical improvement.\n\nB. During the initial episode, increase pyridostigmine dose and administer edrophonium to distinguish crisis type; during the subsequent episode, treat with atropine and proceed directly to surgery.\n\nC. During the initial episode, administer pralidoxime with atropine while continuing cholinesterase inhibitor therapy; during the subsequent episode, start Intravenous Immunoglobulin (IVIG) and schedule surgery within $24$ hours regardless of respiratory metrics.\n\nD. During the initial episode, perform emergent thymectomy to remove the antigen source; during the subsequent episode, initiate high-dose corticosteroids immediately preoperatively without IVIG or plasma exchange.\n\nE. During the initial episode, manage with ventilatory support alone and continue pyridostigmine to prevent weakness; during the subsequent episode, prefer IVIG because it is less invasive and has a faster onset than plasma exchange.", "solution": "The problem is valid. It presents a clinically realistic and critical decision-making scenario grounded in fundamental pathophysiology and pharmacology. It provides all necessary information to distinguish between cholinergic and myasthenic crises and to select an appropriate management strategy based on the given principles (definitions of crisis types, indications for ventilation, mechanism/onset of immunotherapies). The question is well-posed and objective.\n\n**Derivation**\n\nThe management must be broken down into two phases corresponding to the two clinical episodes.\n\n**Episode 1: Initial Presentation**\n*   **Diagnosis**: The patient presents with acute weakness after a recent *increase* in his pyridostigmine dose. The key diagnostic features are the signs of excessive muscarinic stimulation: prominent salivation, bronchorrhea (excessive secretions), abdominal cramping, diarrhea, miosis (constricted pupils), and bradycardia. These are the classic \"DUMBELS\" signs. The muscle fasciculations are a sign of nicotinic receptor overstimulation. This clinical picture is pathognomonic for a **cholinergic crisis** due to an overdose of cholinesterase inhibitor.\n*   **Management**: The patient's respiratory status indicates impending respiratory failure, as his FVC ($12 \\ \\mathrm{mL/kg}$) is below the critical threshold of $15 \\ \\mathrm{mL/kg}$ and his NIF ($-15 \\ \\text{cmH}_2\\text{O}$) is less negative than the threshold of $-20 \\ \\text{cmH}_2\\text{O}$.\n    1.  **Airway Management**: Immediate intubation and mechanical ventilation are required to protect the airway and support breathing.\n    2.  **Stop the Offending Agent**: Pyridostigmine must be discontinued immediately as it is the cause of the crisis.\n    3.  **Manage Muscarinic Symptoms**: Intravenous atropine is required to counteract the life-threatening muscarinic effects of bradycardia and bronchorrhea. Atropine is a muscarinic antagonist and will not affect the muscle weakness (a nicotinic effect).\n\n**Episode 2: Subsequent Deterioration**\n*   **Diagnosis**: After withholding pyridostigmine, the patient's weakness returns and progresses over 24 hours. This time, the clinical signs are of pure muscle weakness (dyspnea, dysphagia, limb weakness) accompanied by signs of sympathetic stress (tachycardia, dilated pupils) and a lack of secretions. A new infiltrate suggests an aspiration event, which is a common trigger for a crisis. This clinical picture, occurring after withdrawal of medication and in the presence of a trigger, is characteristic of a **myasthenic crisis**. The respiratory metrics (FVC $10 \\ \\mathrm{mL/kg}$, NIF $-12 \\ \\text{cmH}_2\\text{O}$) confirm severe respiratory failure.\n*   **Management**: The goal is to rapidly improve the patient's immunologic status to allow for safe extubation and to proceed with the necessary thymectomy.\n    1.  **Supportive Care**: Continued ventilatory support is essential.\n    2.  **Rapid Immunomodulation**: To prepare for surgery within 72 hours, a rapid-acting therapy is needed. According to the provided principles, therapeutic plasma exchange (PLEX) has an onset of action in 24-48 hours, while IVIG has a slower onset of 2-5 days. Therefore, **therapeutic plasma exchange** is the superior choice to achieve rapid preoperative stabilization within the desired timeframe.\n\n**Analysis of Options:**\n*   **A. During the initial episode, intubate for ventilatory support, administer intravenous atropine, and temporarily discontinue pyridostigmine; during the subsequent episode, initiate therapeutic plasma exchange to achieve rapid preoperative stabilization and proceed to thymectomy after clinical improvement.** This option correctly identifies the management for both cholinergic crisis (intubation, atropine, stop drug) and the subsequent myasthenic crisis (PLEX for rapid improvement before surgery). This is the correct choice.\n*   **B. During the initial episode, increase pyridostigmine dose and administer edrophonium to distinguish crisis type; during the subsequent episode, treat with atropine and proceed directly to surgery.** Increasing pyridostigmine would be fatal in a cholinergic crisis. An edrophonium (Tensilon) test is contraindicated as it can worsen a cholinergic crisis and is dangerous in a patient with respiratory failure. Proceeding directly to surgery in an unstable patient is incorrect.\n*   **C. During the initial episode, administer pralidoxime with atropine while continuing cholinesterase inhibitor therapy; during the subsequent episode, start Intravenous Immunoglobulin (IVIG) and schedule surgery within 24 hours regardless of respiratory metrics.** Pralidoxime is an antidote for irreversible organophosphate cholinesterase inhibitors, not for the reversible inhibitor pyridostigmine. Continuing pyridostigmine is incorrect. IVIG is slower than PLEX, and proceeding to surgery without clinical improvement is unsafe.\n*   **D. During the initial episode, perform emergent thymectomy to remove the antigen source; during the subsequent episode, initiate high-dose corticosteroids immediately preoperatively without IVIG or plasma exchange.** Emergent thymectomy in a critically ill, unstable patient is contraindicated. While thymectomy is the long-term solution, the patient must be stabilized first. High-dose steroids can cause a transient worsening of myasthenia and are not a rapid optimization strategy.\n*   **E. During the initial episode, manage with ventilatory support alone and continue pyridostigmine to prevent weakness; during the subsequent episode, prefer IVIG because it is less invasive and has a faster onset than plasma exchange.** Continuing pyridostigmine is incorrect. The premise that IVIG has a faster onset than plasma exchange is directly contradicted by the fundamental bases provided in the problem statement.", "answer": "$$\\boxed{A}$$", "id": "5194822"}, {"introduction": "Optimizing a high-risk patient for surgery requires moving beyond qualitative goals to precise, quantitative planning. Therapeutic plasma exchange (TPE) is a powerful tool for reducing pathogenic antibody levels in myasthenia gravis, but its effectiveness depends on a rationally designed schedule. This exercise guides you through the application of a pharmacokinetic model to determine the necessary number and timing of TPE sessions, demonstrating how a principled, mathematical approach ensures a patient's immunological status is ideal at the time of thymectomy [@problem_id:5194850].", "problem": "A patient with thymoma and Myasthenia Gravis (MG) is scheduled for extended thymectomy in $T_{s} = 192$ hours. To optimize neuromuscular transmission, you plan preoperative Therapeutic Plasma Exchange (TPE; plasmapheresis) to reduce the serum anti–Acetylcholine Receptor (AChR) antibody titer measured in the intravascular compartment. Assume a two-compartment immunoglobulin distribution model with an intravascular fraction $\\beta$ and extravascular fraction $1 - \\beta$, rapid intravascular removal by TPE, and first-order intercompartmental re-equilibration between exchanges. The following well-tested facts and parameters apply:\n\n- Each TPE exchange removes a fraction $\\eta = 0.60$ of the intravascular anti-AChR antibody mass instantaneously.\n- In steady state, the intravascular fraction is $\\beta = 0.40$ of the total body antibody mass.\n- Intercompartmental re-equilibration (movement of antibody from extravascular to intravascular space) follows first-order kinetics with rate constant $k$ related to a distribution half-time $t_{1/2}$ by $k = (\\ln 2)/t_{1/2}$, with $t_{1/2} = 24 \\ \\mathrm{h}$.\n- Antibody synthesis and catabolism are negligible over the preoperative window.\n- Before each exchange, if at least $24 \\ \\mathrm{h}$ have elapsed since the prior exchange, assume the intravascular fraction has re-equilibrated to $Q_{v} = \\beta Q$, where $Q$ is the current total antibody mass.\n- The final exchange ends $\\Delta t_{N} = 6 \\ \\mathrm{h}$ before incision.\n\nLet the baseline steady-state serum titer (proportional to intravascular antibody mass $Q_{v}(0)$) be $C_{0}$, and let the target pre-incision titer be at or below a fraction $r_{\\mathrm{target}} = 0.10$ of baseline, i.e., $C(T_{s})/C_{0} \\leq r_{\\mathrm{target}}$.\n\nStarting from mass balance and first-order re-equilibration, derive the expression for the post-schedule serum titer fraction at incision as a function of the number of exchanges $N$ and the final interval $\\Delta t_{N}$, identify the minimal integer $N$ that achieves $C(T_{s})/C_{0} \\leq 0.10$ under the above assumptions, and specify a valid schedule by listing the exchange end-times (in hours before incision) for $N$ exchanges spaced by $24 \\ \\mathrm{h}$, with the last exchange ending $\\Delta t_{N} = 6 \\ \\mathrm{h}$ before incision.\n\nRound all time values to four significant figures and express time entries in hours. Provide your final answer as a single row matrix whose first entry is $N$ followed by the ordered list of exchange end-times (from earliest to latest before incision).", "solution": "The problem is first validated to ensure it is scientifically grounded, well-posed, and objective. The problem describes a standard two-compartment pharmacokinetic model, a valid simplification used in clinical settings for modeling substance distribution and elimination. The parameters provided are plausible, and the objectives are clearly defined. All necessary information is given, and there are no internal contradictions. The problem is deemed valid.\n\nThe solution is developed in three stages: first, deriving a general expression for the serum titer after a series of therapeutic plasma exchanges (TPE); second, determining the minimum number of exchanges $N$ to meet the therapeutic goal; and third, defining the specific schedule for these exchanges.\n\nLet $Q_{v}(t)$ and $Q_{e}(t)$ be the intravascular and extravascular anti-AChR antibody masses at time $t$, respectively. The total antibody mass is $Q(t) = Q_{v}(t) + Q_{e}(t)$. The serum titer, $C(t)$, is directly proportional to the intravascular mass, $Q_{v}(t)$. Therefore, the titer fraction relative to baseline is $C(t)/C_{0} = Q_{v}(t)/Q_{v}(0)$.\n\nAt baseline ($t=0$), the system is in steady state. The total initial mass is $Q_{0}$. The intravascular and extravascular masses are given by:\n$Q_{v}(0) = \\beta Q_{0}$\n$Q_{e}(0) = (1-\\beta) Q_{0}$\nwhere $\\beta = 0.40$ is the steady-state intravascular fraction.\n\nThe process consists of $N$ cycles of TPE followed by re-equilibration. The problem states that for intervals of at least $24 \\ \\mathrm{h}$, we are to assume that the antibody distribution returns to steady state, i.e., $Q_{v} = \\beta Q$ where $Q$ is the current total antibody mass. The planned exchanges are separated by $24 \\ \\mathrm{h}$.\n\nLet's model the effect of one TPE cycle. Let $Q_{i-1}$ be the total antibody mass just before the $i$-th exchange. Due to the re-equilibration assumption, the intravascular mass just before the exchange is $Q_{v,i}^{-} = \\beta Q_{i-1}$.\nThe TPE procedure instantaneously removes a fraction $\\eta = 0.60$ of the intravascular mass. The mass immediately after the exchange, $Q_{v,i}^{+}$, is:\n$Q_{v,i}^{+} = (1-\\eta) Q_{v,i}^{-} = (1-\\eta) \\beta Q_{i-1}$\nThe extravascular mass is unaffected by the exchange: $Q_{e,i}^{+} = Q_{e,i}^{-} = (1-\\beta) Q_{i-1}$.\nThe new total body antibody mass after the $i$-th exchange, $Q_{i}$, is the sum of the post-exchange masses:\n$Q_{i} = Q_{v,i}^{+} + Q_{e,i}^{+} = (1-\\eta) \\beta Q_{i-1} + (1-\\beta) Q_{i-1} = (1 - \\eta\\beta) Q_{i-1}$\n\nThis establishes a recurrence relation for the total antibody mass. Starting with $Q_{0}$, the total mass after $i$ exchanges is $Q_{i} = (1-\\eta\\beta)^{i} Q_{0}$.\nSo, after $N-1$ exchanges and subsequent re-equilibration, the total mass just before the $N$-th exchange is $Q_{N-1} = (1-\\eta\\beta)^{N-1} Q_{0}$.\n\nNow we consider the $N$-th exchange and the final post-exchange interval.\nJust before the $N$-th exchange, the intravascular mass is $Q_{v,N}^{-} = \\beta Q_{N-1} = \\beta (1-\\eta\\beta)^{N-1} Q_{0}$.\nImmediately after the $N$-th exchange, the intravascular mass is:\n$Q_{v,N}^{+} = (1-\\eta) Q_{v,N}^{-} = (1-\\eta) \\beta (1-\\eta\\beta)^{N-1} Q_{0}$.\nThe total mass after the $N$-th exchange is $Q_{N} = (1-\\eta\\beta) Q_{N-1} = (1-\\eta\\beta)^{N} Q_{0}$.\n\nFollowing the final exchange, there is a re-equilibration period of duration $\\Delta t_{N} = 6 \\ \\mathrm{h}$. During this shorter interval, we cannot assume full re-equilibration. We must use the first-order kinetic equation for intercompartmental transfer:\n$\\frac{dQ_{v}}{dt} = k (\\beta Q - Q_{v})$\nwhere $k = (\\ln 2)/t_{1/2}$ and $Q$ is the constant total mass during this interval, $Q = Q_{N}$.\nThe solution to this linear ordinary differential equation for $Q_{v}(t)$ over a time interval $\\Delta t$, starting from an initial value $Q_{v,\\text{start}}$, is:\n$Q_{v}(t_0 + \\Delta t) = (Q_{v,\\text{start}} - \\beta Q) \\exp(-k \\Delta t) + \\beta Q$.\n\nFor the final interval, $t_0$ is the time of the end of the $N$-th exchange, $\\Delta t = \\Delta t_{N}$, $Q_{v,\\text{start}} = Q_{v,N}^{+}$, and $Q = Q_{N}$. The intravascular mass at the time of surgery, $T_{s}$, is:\n$Q_{v}(T_{s}) = (Q_{v,N}^{+} - \\beta Q_{N}) \\exp(-k \\Delta t_{N}) + \\beta Q_{N}$.\n\nSubstituting the expressions for $Q_{v,N}^{+}$ and $Q_{N}$:\n$Q_{v}(T_{s}) = \\left[ (1-\\eta) \\beta (1-\\eta\\beta)^{N-1} Q_{0} - \\beta (1-\\eta\\beta)^{N} Q_{0} \\right] \\exp(-k \\Delta t_{N}) + \\beta (1-\\eta\\beta)^{N} Q_{0}$.\nFactoring out $\\beta Q_{0} (1-\\eta\\beta)^{N-1}$ from the bracketed term:\n$Q_{v}(T_{s}) = \\beta Q_{0} (1-\\eta\\beta)^{N-1} \\left[ (1-\\eta) - (1-\\eta\\beta) \\right] \\exp(-k \\Delta t_{N}) + \\beta (1-\\eta\\beta)^{N} Q_{0}$.\nThe term in the new bracket simplifies: $(1-\\eta) - (1-\\eta\\beta) = -\\eta + \\eta\\beta = -\\eta(1-\\beta)$.\n$Q_{v}(T_{s}) = -\\eta(1-\\beta) \\beta Q_{0} (1-\\eta\\beta)^{N-1} \\exp(-k \\Delta t_{N}) + \\beta (1-\\eta\\beta)^{N} Q_{0}$.\n\nThe desired quantity is the titer fraction $C(T_{s})/C_{0} = Q_{v}(T_{s})/Q_{v}(0) = Q_{v}(T_{s})/(\\beta Q_{0})$.\n$\\frac{C(T_{s})}{C_{0}} = \\frac{1}{\\beta Q_{0}} \\left[ -\\eta(1-\\beta) \\beta Q_{0} (1-\\eta\\beta)^{N-1} \\exp(-k \\Delta t_{N}) + \\beta (1-\\eta\\beta)^{N} Q_{0} \\right]$\n$\\frac{C(T_{s})}{C_{0}} = - \\eta(1-\\beta) (1-\\eta\\beta)^{N-1} \\exp(-k \\Delta t_{N}) + (1-\\eta\\beta)^{N}$.\nFactoring out $(1-\\eta\\beta)^{N-1}$, we obtain the derived expression:\n$\\frac{C(T_{s})}{C_{0}} = (1-\\eta\\beta)^{N-1} \\left[ (1-\\eta\\beta) - \\eta(1-\\beta) \\exp(-k \\Delta t_{N}) \\right]$.\n\nNext, we find the minimal integer $N$ to achieve $C(T_{s})/C_{0} \\leq r_{\\mathrm{target}} = 0.10$.\nWe substitute the given values: $\\eta=0.60$, $\\beta=0.40$, $t_{1/2}=24 \\ \\mathrm{h}$, $\\Delta t_{N}=6 \\ \\mathrm{h}$.\n$1-\\eta\\beta = 1 - (0.60)(0.40) = 1 - 0.24 = 0.76$.\n$k = \\frac{\\ln 2}{24} \\ \\mathrm{h}^{-1}$.\n$k \\Delta t_{N} = \\frac{\\ln 2}{24} \\times 6 = \\frac{\\ln 2}{4}$.\n$\\exp(-k \\Delta t_{N}) = \\exp(-\\frac{\\ln 2}{4}) = (2^{-1})^{1/4} = 2^{-1/4}$.\n$\\eta(1-\\beta) = 0.60(1-0.40) = 0.60(0.60) = 0.36$.\n\nThe inequality becomes:\n$(0.76)^{N-1} \\left[ 0.76 - 0.36 \\times 2^{-1/4} \\right] \\leq 0.10$.\nThe term in the brackets is approximately $0.76 - 0.36 \\times 0.8409 = 0.76 - 0.3027 = 0.4573$.\n$(0.76)^{N-1} (0.457277...) \\leq 0.10$.\n$(0.76)^{N-1} \\leq \\frac{0.10}{0.457277...} \\approx 0.218686$.\nTaking the natural logarithm of both sides:\n$(N-1)\\ln(0.76) \\leq \\ln(0.218686)$.\nSince $\\ln(0.76)$ is negative, we reverse the inequality upon division:\n$N-1 \\geq \\frac{\\ln(0.218686)}{\\ln(0.76)} \\approx \\frac{-1.5200}{-0.2744} \\approx 5.539$.\n$N \\geq 6.539$.\nThe minimal integer number of exchanges is $N=7$.\n\nFinally, we determine the schedule. The last ($7^{th}$) exchange ends $\\Delta t_{N} = 6 \\ \\mathrm{h}$ before incision. The exchanges are spaced by $24 \\ \\mathrm{h}$. The times are requested in hours before incision, ordered from the earliest event to the latest.\nLet $t_{i}$ be the end-time of the $i$-th exchange in hours before incision.\n$t_7 = 6.000 \\ \\mathrm{h}$.\nThe time between the end of exchange $i-1$ and the end of exchange $i$ is $24 \\ \\mathrm{h}$, so $t_{i-1} = t_i + 24$.\n$t_6 = t_7 + 24 = 6 + 24 = 30.00 \\ \\mathrm{h}$.\n$t_5 = t_6 + 24 = 30 + 24 = 54.00 \\ \\mathrm{h}$.\n$t_4 = t_5 + 24 = 54 + 24 = 78.00 \\ \\mathrm{h}$.\n$t_3 = t_4 + 24 = 78 + 24 = 102.0 \\ \\mathrm{h}$.\n$t_2 = t_3 + 24 = 102 + 24 = 126.0 \\ \\mathrm{h}$.\n$t_1 = t_2 + 24 = 126 + 24 = 150.0 \\ \\mathrm{h}$.\nThe full schedule of exchange end-times, from earliest to latest before incision, is $(150.0, 126.0, 102.0, 78.00, 54.00, 30.00, 6.000)$ hours. The total duration from the first exchange to surgery is $150.0 \\ \\mathrm{h}$, which is within the available preoperative window of $T_s = 192 \\ \\mathrm{h}$.\n\nThe final answer consists of $N=7$ and the list of scheduled times, presented in a single row matrix.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n7 & 150.0 & 126.0 & 102.0 & 78.00 & 54.00 & 30.00 & 6.000\n\\end{pmatrix}\n}\n$$", "id": "5194850"}]}